Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.

Guenther G Steger; Daniel Egle; Rupert Bartsch; Georg Pfeiler; Edgar Petru; Richard Greil; Ruth Helfgott; Christian Marth; Leopold Öhler; Michael Hubalek; Alois Lang; Christoph Tinchon; Ferdinand Haslbauer; Andreas Redl; Karin Hock; Mathias Hennebelle; Bernhard Mraz; Michael Gnant

doi:10.1016/j.breast.2020.01.035

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.

Guenther G Steger, Daniel Egle, Rupert Bartsch, Georg Pfeiler, Edgar Petru, Richard Greil (Co-author), Ruth Helfgott, Christian Marth, Leopold Öhler, Michael Hubalek, Alois Lang, Christoph Tinchon, Ferdinand Haslbauer, Andreas Redl, Karin Hock, Mathias Hennebelle, Bernhard Mraz, Michael Gnant

Ordensklinikum Linz, KH Barmherzige Schwestern

Research output: Contribution to journal › Original Article › peer-review

12 Citations (Web of Science)

Original language	English
Pages (from-to)	64-70
Journal	BREAST
Volume	50
DOIs	https://doi.org/10.1016/j.breast.2020.01.035
Publication status	Published - 2020

Keywords

POSTMENOPAUSAL
MANAGEMENT

Access to Document

10.1016/j.breast.2020.01.035

Cite this

Steger, G. G., Egle, D., Bartsch, R., Pfeiler, G., Petru, E., Greil, R., Helfgott, R., Marth, C., Öhler, L., Hubalek, M., Lang, A., Tinchon, C., Haslbauer, F., Redl, A., Hock, K., Hennebelle, M., Mraz, B., & Gnant, M. (2020). Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. BREAST , 50, 64-70. https://doi.org/10.1016/j.breast.2020.01.035

Steger, Guenther G ; Egle, Daniel ; Bartsch, Rupert et al. / Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. In: BREAST 2020 ; Vol. 50. pp. 64-70.

@article{aa5e5567c7204683932aacdd75e349d6,

title = "Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.",

keywords = "POSTMENOPAUSAL, MANAGEMENT",

author = "Steger, {Guenther G} and Daniel Egle and Rupert Bartsch and Georg Pfeiler and Edgar Petru and Richard Greil and Ruth Helfgott and Christian Marth and Leopold {\"O}hler and Michael Hubalek and Alois Lang and Christoph Tinchon and Ferdinand Haslbauer and Andreas Redl and Karin Hock and Mathias Hennebelle and Bernhard Mraz and Michael Gnant",

note = "Lehr-KH Ordensklinikum Linz: Hospital Sisters of Charity, Linz, Linz, Austria; Greil: Department of Oncology, Medical University of Salzburg, Salzburg, Austria",

year = "2020",

doi = "10.1016/j.breast.2020.01.035",

language = "English",

volume = "50",

pages = "64--70",

journal = "BREAST ",

issn = "0960-9776",

}

Steger, GG, Egle, D, Bartsch, R, Pfeiler, G, Petru, E, Greil, R, Helfgott, R, Marth, C, Öhler, L, Hubalek, M, Lang, A, Tinchon, C, Haslbauer, F, Redl, A, Hock, K, Hennebelle, M, Mraz, B & Gnant, M 2020, 'Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.', BREAST , vol. 50, pp. 64-70. https://doi.org/10.1016/j.breast.2020.01.035

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. / Steger, Guenther G; Egle, Daniel; Bartsch, Rupert et al.
In: BREAST , Vol. 50, 2020, p. 64-70.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.

AU - Steger, Guenther G

AU - Egle, Daniel

AU - Bartsch, Rupert

AU - Pfeiler, Georg

AU - Petru, Edgar

AU - Greil, Richard

AU - Helfgott, Ruth

AU - Marth, Christian

AU - Öhler, Leopold

AU - Hubalek, Michael

AU - Lang, Alois

AU - Tinchon, Christoph

AU - Haslbauer, Ferdinand

AU - Redl, Andreas

AU - Hock, Karin

AU - Hennebelle, Mathias

AU - Mraz, Bernhard

AU - Gnant, Michael

N1 - Lehr-KH Ordensklinikum Linz: Hospital Sisters of Charity, Linz, Linz, Austria; Greil: Department of Oncology, Medical University of Salzburg, Salzburg, Austria

PY - 2020

Y1 - 2020

KW - POSTMENOPAUSAL

KW - MANAGEMENT

U2 - 10.1016/j.breast.2020.01.035

DO - 10.1016/j.breast.2020.01.035

M3 - Original Article

C2 - 32062536

SN - 0960-9776

VL - 50

SP - 64

EP - 70

JO - BREAST

JF - BREAST

ER -

Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R et al. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. BREAST . 2020;50:64-70. doi: 10.1016/j.breast.2020.01.035